Table 5.
Change in paw volume (ml) and percent inhibition (%) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Group | 0 h | 1 h | % | 2 h | % | 3 h | % | 4 h | % | 5 h | % |
TE | 0.43 ± 0.01 | 0.57 ± 0.01 | – | 0.73 ± 0.01 | – | 0.76 ± 0.01 | – | 0.81 ± 0.02 | – | 0.88 ± 0.04 | – |
ASA | 0.42 ± 0.01 | 0.51 ± 0.02a3c1d1 | 36.1 | 0.53 ± 0.01a3c3d3g3 | 63.9 | 0.58 ± 0.02a3c3d3h1 | 50.8 | 0.64 ± 0.01a3c3d3g3 | 42.6 | 0.67 ± 0.01a3c3d3g3 | 45.3 |
CF 100 | 0.43 ± 0.01 | 0.57 ± 0.01 | 4.5 | 0.68 ± 0.01 | 15.1 | 0.72 ± 0.03 | 11.4 | 0.79 ± 0.01 | 4.8 | 0.85 ± 0.01 | 6.3 |
CF 200 | 0.44 ± 0.01 | 0.56 ± 0.01 | 7.7 | 0.67 ± 0.01 | 18.2 | 0.72 ± 0.02 | 12.9 | 0.78 ± 0.02 | 9.5 | 0.85 ± 0.01 | 9.2 |
CF 400 | 0.45 ± 0.01 | 0.58 ± 0.01 | 2.3 | 0.67 ± 0.01a1h3 | 24.4 | 0.70 ± 0.01a1h1 | 22.8 | 0.76 ± 0.01a2f1h3 | 18.0 | 0.80 ± 0.01a3h3 | 20.8 |
MF 100 | 0.42 ± 0.01 | 0.54 ± 0.01 | 11.3 | 0.63 ± 0.02a3h1 | 26.8 | 0.67 ± 0.01a3b3 | 24.0 | 0.71 ± 0.01a3h1 | 22.8 | 0.76 ± 0.01a3h2 | 23.4 |
MF 200 | 0.45 ± 0.01 | 0.57 ± 0.01 | 3.8 | 0.64 ± 0.01a3h2 | 33.0 | 0.69 ± 0.01a2b3 | 25.2 | 0.73 ± 0.01a3h2 | 25.4 | 0.78 ± 0.01a3h3 | 26.3 |
MF 400 | 0.44 ± 0.01 | 0.54 ± 0.02 | 21.8 | 0.58 ± 0.01a3 | 52.2 | 0.64 ± 0.02a3b1 | 37.2 | 0.68 ± 0.03a3e3 | 36.8 | 0.71 ± 0.01a3 | 39.7 |
Values are expressed as Mean ± S.E.M (n = 6); aagainst the control, bagainst the standard drug, cagainst CF100, dagainst CF200, eagainst CF400, fagainst MF 100, gagainst MF 200, hagainst MF 400. 1 P < 0.05, 2 P < 0.01, 3 P < 0.001; TE tween 80, ASA: aspirin, CF and MF refers to chloroform and methanol fractions of Moringa stenopetala respectively; control received 2% Tween 80, 10 ml/kg, whereas:ASA, standard received Aspirin 100 mg/kg orally; Numbers refer to dose in mg/kg